Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Insulin Aspart in Subjects With Type 1 Diabetes
Public ClinicalTrials.gov record NCT00612040. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 16 Week Randomised, Open Labelled, 3-armed, Treat-to-target, Parallel Group Trial Comparing SIBA (D) Once Daily + NovoRapid®, SIBA (E) Once Daily + NovoRapid® and Insulin Glargine Once Daily + NovoRapid®, All in a Basal/Bolus Regimen in Subjects With Type 1 Diabetes
Study identification
- NCT ID
- NCT00612040
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Enrollment
- 178 participants
Conditions and interventions
Conditions
Interventions
- insulin aspart Drug
- insulin degludec Drug
- insulin glargine Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2007
- Primary completion
- May 31, 2008
- Completion
- May 31, 2008
- Last update posted
- Mar 2, 2017
2008
United States locations
- U.S. sites
- 9
- U.S. states
- 8
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novo Nordisk Investigational Site | Walnut Creek | California | 94598 | — |
| Novo Nordisk Investigational Site | Honolulu | Hawaii | 96814 | — |
| Novo Nordisk Investigational Site | Idaho Falls | Idaho | 83404-7596 | — |
| Novo Nordisk Investigational Site | Des Moines | Iowa | 50314 | — |
| Novo Nordisk Investigational Site | Hyattsville | Maryland | 20782 | — |
| Novo Nordisk Investigational Site | Chattanooga | Tennessee | 37404 | — |
| Novo Nordisk Investigational Site | Dallas | Texas | 75230 | — |
| Novo Nordisk Investigational Site | Dallas | Texas | 75231 | — |
| Novo Nordisk Investigational Site | Renton | Washington | 98057 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 24 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00612040, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 2, 2017 · Synced May 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00612040 live on ClinicalTrials.gov.